FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548978596> ?p ?o ?g. }

• W2548978596 endingPage "110" @default.
• W2548978596 startingPage "110" @default.
• W2548978596 abstract "Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common form of adult lymphoma. Although comprehensively investigated, it remains a prominently heterogeneous disease. The standard of care for DLBCL is a combination chemo-immunotherapy RCHOP regimen. The 3-year progression free survival (PFS) rate is 70%. Relapses normally occur within 2-3 years and treatment options for relapsed and refractory DLBCL are limited with only 10% of patients achieving a 3-year PFS. Global mRNA expression analysis has been used to further classify DLBCL into molecularly distinct subtypes (GCB and ABC) which display remarkably different outcomes to current therapeutics, with GCB having a better prognostic outcome. Multiple attempts at further restratification of DLBCL cases based on next generation sequencing have only confirmed the striking heterogeneity of the disease; providing little direction for clinical practices. Therefore, further analysis of DLBCL with the intent to stratify patients for clinical response is needed. We utilized whole exome sequencing to reveal alterations in the genome that are associated with relapse and chemotherapeutic resistance in DLBCL. Current literature has focused on DLBCL as an entity without stratification into relapsed/refractory and de novo DLBCL. In addition, published studies have had a clear focus on diagnostic sampling. By discovering and prioritizing somatic mutations associated with relapse and chemotherapeutic resistance, we aim to provide a novel analysis of the mutational heterogeneity of DLBCL to identify new biomarkers for improved stratification of patients for clinical treatment. Method: DLBCL samples from 37 cases (45 biopsies) were collected with normal matched blood (germline). Of these, 17 cases never relapsed (median observation time 3.9 yrs). Whereas, 20 cases relapsed from RCHOP or related therapy (median observation time 4.8 yrs). Of these, 15 biopsies were taken at diagnosis and 13 were taken at relapse including 8 cases with serial biopsies. We performed whole exome capture and paired-end sequencing using the Illumina HiSeq2000 platform. Reads of each sample were mapped with BWA-mem to the human reference genome (build b37 with an added decoy contig). Marking of duplicates was performed with Picard tools; GATK tools were used for two‐step local realignment and base‐quality recalibration. Somatic single nucleotide variant (SNV) detection was performed with MuTect and Strelka. Strelka alone was used for insertion/deletion (InDel) detection. Results: We achieved 288X mean coverage of targeted exonic regions in tumor samples and 125X in normal blood. After application of our bioinformatics pipeline, we identified 44,297 variants in the cohort. The mean mutational SNV burden was 944 and the mean InDel burden was 40 variants per case. In serial biopsies there was a higher mean mutational burden at relapse than diagnosis (1001 to 772, respectively). After filtering synonymous, UTR, non-coding, and low confidence variant calls, we identified 11,743 coding variants corresponding to 6,399 genes (Figure 1). In order to define potential recurrent driver mutations in DLBCL associated with relapse and survival, we applied the Oncodrive algorithm (IntOgen) to the total cohort and subgroups classified by relapse status, survival and subtype. We also applied the Oncocluster algorithm (IntOgen) to the total cohort to identify genes with significant hotspots and clustering which may suggest potential cancer driver mutations. Using a corrected q-value of <.1 we identified 102 potential driver mutations. Within our driver mutations we identified many of the previously discovered genes associated with DLBCL including; MLL2, B2M, CD58, MEF2B, FOXO1, TP53, PIM1, SOCS1, MYC, GNA13, SGK1, TNFAIP3, MYD88, PRDM1, CDKN2A, EZH2 and CIITA. However, as previously reported, our gene list does not extensively overlap with earlier DLBCL exome sequencing reports (Figure 2). This may, in part, be due to differing library preparations, sequencing methods, bioinformatic pipelines and criteria for gene selection, yet it also represents the heterogeneity of DLBCL as a neoplastic entity. Given the underlying heterogeneity of DLBCL, by focusing on relapse and survival status of our cohort the gene variants generated and analyzed in our analysis will provide a novel view of the DLBCL mutational landscape from the perspective of relapse and chemoresistance. Disclosures No relevant conflicts of interest to declare." @default.
• W2548978596 created "2016-11-11" @default.
• W2548978596 creator A5004859097 @default.
• W2548978596 creator A5006517353 @default.
• W2548978596 creator A5006641494 @default.
• W2548978596 creator A5007823953 @default.
• W2548978596 creator A5009481797 @default.
• W2548978596 creator A5022804854 @default.
• W2548978596 creator A5031803655 @default.
• W2548978596 creator A5038023987 @default.
• W2548978596 creator A5040680720 @default.
• W2548978596 creator A5048772849 @default.
• W2548978596 creator A5076275499 @default.
• W2548978596 creator A5088720489 @default.
• W2548978596 date "2015-12-03" @default.
• W2548978596 modified "2023-09-26" @default.
• W2548978596 title "Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-Cell Lymphoma" @default.
• W2548978596 doi "https://doi.org/10.1182/blood.v126.23.110.110" @default.
• W2548978596 hasPublicationYear "2015" @default.
• W2548978596 type Work @default.
• W2548978596 sameAs 2548978596 @default.
• W2548978596 citedByCount "1" @default.
• W2548978596 countsByYear W25489785962018 @default.
• W2548978596 crossrefType "journal-article" @default.
• W2548978596 hasAuthorship W2548978596A5004859097 @default.
• W2548978596 hasAuthorship W2548978596A5006517353 @default.
• W2548978596 hasAuthorship W2548978596A5006641494 @default.
• W2548978596 hasAuthorship W2548978596A5007823953 @default.
• W2548978596 hasAuthorship W2548978596A5009481797 @default.
• W2548978596 hasAuthorship W2548978596A5022804854 @default.
• W2548978596 hasAuthorship W2548978596A5031803655 @default.
• W2548978596 hasAuthorship W2548978596A5038023987 @default.
• W2548978596 hasAuthorship W2548978596A5040680720 @default.
• W2548978596 hasAuthorship W2548978596A5048772849 @default.
• W2548978596 hasAuthorship W2548978596A5076275499 @default.
• W2548978596 hasAuthorship W2548978596A5088720489 @default.
• W2548978596 hasConcept C104317684 @default.
• W2548978596 hasConcept C121608353 @default.
• W2548978596 hasConcept C126322002 @default.
• W2548978596 hasConcept C143998085 @default.
• W2548978596 hasConcept C16671776 @default.
• W2548978596 hasConcept C2778336483 @default.
• W2548978596 hasConcept C2778559949 @default.
• W2548978596 hasConcept C2779338263 @default.
• W2548978596 hasConcept C501734568 @default.
• W2548978596 hasConcept C54355233 @default.
• W2548978596 hasConcept C71924100 @default.
• W2548978596 hasConcept C86803240 @default.
• W2548978596 hasConceptScore W2548978596C104317684 @default.
• W2548978596 hasConceptScore W2548978596C121608353 @default.
• W2548978596 hasConceptScore W2548978596C126322002 @default.
• W2548978596 hasConceptScore W2548978596C143998085 @default.
• W2548978596 hasConceptScore W2548978596C16671776 @default.
• W2548978596 hasConceptScore W2548978596C2778336483 @default.
• W2548978596 hasConceptScore W2548978596C2778559949 @default.
• W2548978596 hasConceptScore W2548978596C2779338263 @default.
• W2548978596 hasConceptScore W2548978596C501734568 @default.
• W2548978596 hasConceptScore W2548978596C54355233 @default.
• W2548978596 hasConceptScore W2548978596C71924100 @default.
• W2548978596 hasConceptScore W2548978596C86803240 @default.
• W2548978596 hasIssue "23" @default.
• W2548978596 hasLocation W25489785961 @default.
• W2548978596 hasOpenAccess W2548978596 @default.
• W2548978596 hasPrimaryLocation W25489785961 @default.
• W2548978596 hasRelatedWork W2093676674 @default.
• W2548978596 hasRelatedWork W2247758784 @default.
• W2548978596 hasRelatedWork W2307119183 @default.
• W2548978596 hasRelatedWork W2469609771 @default.
• W2548978596 hasRelatedWork W2547706183 @default.
• W2548978596 hasRelatedWork W2575338530 @default.
• W2548978596 hasRelatedWork W2610140576 @default.
• W2548978596 hasRelatedWork W2618854496 @default.
• W2548978596 hasRelatedWork W2895830251 @default.
• W2548978596 hasRelatedWork W2937863780 @default.
• W2548978596 hasRelatedWork W2944597003 @default.
• W2548978596 hasRelatedWork W2979954019 @default.
• W2548978596 hasRelatedWork W2980076240 @default.
• W2548978596 hasRelatedWork W3000127461 @default.
• W2548978596 hasRelatedWork W3030734620 @default.
• W2548978596 hasRelatedWork W3112702634 @default.
• W2548978596 hasRelatedWork W3118529322 @default.
• W2548978596 hasRelatedWork W3139217668 @default.
• W2548978596 hasRelatedWork W3140430527 @default.
• W2548978596 hasRelatedWork W3213103202 @default.
• W2548978596 hasVolume "126" @default.
• W2548978596 isParatext "false" @default.
• W2548978596 isRetracted "false" @default.
• W2548978596 magId "2548978596" @default.
• W2548978596 workType "article" @default.